D
Darwyn Kobasa
Researcher at University of Manitoba
Publications - 61
Citations - 2022
Darwyn Kobasa is an academic researcher from University of Manitoba. The author has contributed to research in topics: Virus & Influenza A virus. The author has an hindex of 18, co-authored 61 publications receiving 1420 citations. Previous affiliations of Darwyn Kobasa include Canadian Science Centre for Human and Animal Health & Public Health Agency of Canada.
Papers
More filters
Journal ArticleDOI
Proteolytic Activation of the 1918 Influenza Virus Hemagglutinin
Chawaree Chaipan,Darwyn Kobasa,Darwyn Kobasa,Stephanie Bertram,Ilona Glowacka,Imke Steffen,Theodros Solomon Tsegaye,Makoto Takeda,Thomas H. Bugge,Semi Kim,Young Woo Park,Andrea Marzi,Stefan Pöhlmann +12 more
TL;DR: It is shown that the previously reported 1918 NA-dependent spread of the 1918 influenza virus is a cell line-dependent phenomenon and is not due to plasminogen recruitment by the 1918 NA, and evidence is provided that TMPRSS2 and TMPR SS4 activate the 1918 HA by cleavage and therefore may promote viral spread in lung tissue.
Journal ArticleDOI
Lethal Influenza Virus Infection in Macaques Is Associated with Early Dysregulation of Inflammatory Related Genes
Cristian Cilloniz,Kyoko Shinya,Xinxia Peng,Marcus J. Korth,Sean Proll,Lauri D. Aicher,Victoria S. Carter,Jean H. Chang,Darwyn Kobasa,Darwyn Kobasa,Friedericke Feldmann,James E. Strong,James E. Strong,Heinz Feldmann,Heinz Feldmann,Yoshihiro Kawaoka,Michael G. Katze +16 more
TL;DR: Compared pathology and global gene expression profiles in bronchial tissue from macaques infected with either the reconstructed 1918 pandemic virus or the highly pathogenic avian H5N1 virus A/Vietnam/1203/04 suggest that the severity of disease in 1918 virus-infected macaques is a consequence of the early up-regulation of cell death and inflammatory related genes, in which additive or synergistic effects likely dictate the severityof tissue damage.
Posted ContentDOI
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Kathryn Westendorf,Stefanie Žentelis,Denisa Foster,Peter Edward Vaillancourt,Wiggin M,Erica Lovett,van der Lee R,Jorg Hendle,A. Pustilnik,Sauder Jm,Lucas Kraft,Yuri Hwang,Robert W. Siegel,Chen J,Beverly A. Heinz,Richard E. Higgs,Kalleward N,Kevin R. Jepson,Rodrigo Goya,Maia A. Smith,David Collins,Davide Pellacani,Ping Xiang,de Puyraimond,Marketa Ricicova,Devorkin L,Pritchard C,O’Neill A,Dalal K,Panwar P,Dhupar H,Garces Fa,Courtney A. Cohen,John M. Dye,Kathleen E. Huie,Catherine V. Badger,Darwyn Kobasa,Darwyn Kobasa,Jonathan Audet,Jonathan Audet,Freitas Jj,Saleema Hassanali,Ina Hughes,Munoz L,Palma Hc,Bharathi Ramamurthy,Cross Rw,Cross Rw,Geisbert Tw,Geisbert Tw,Menacherry,Kumari G. Lokugamage,Borisevich,Lanz I,Lisa Anderson,Sipahimalani P,Kizzmekia S. Corbett,Lingshu Wang,Eun Sung Yang,Yanzhao Zhang,Wei Shi,Barney S. Graham,Mascola,Fernandez Tl,Carl L. Hansen,Ester Falconer,Bryan Edward Jones,Bryan C. Barnhart +67 more
TL;DR: The LY-CoV1404 (also known as bebtelovimab) is a highly potent, neutralizing, SARS CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody identified from a convalescent COVID-19 patient sample, obtained approximately 60 days after symptom onset as mentioned in this paper.
Posted ContentDOI
LY-CoV1404 potently neutralizes SARS-CoV-2 variants
Kathryn Westendorf,Stefanie Žentelis,Denisa Foster,Peter Edward Vaillancourt,Matthew Wiggin,Erica Lovett,Robin van der Lee,Jorg Hendle,A. Pustilnik,J. Michael Sauder,Lucas Kraft,Yuri Hwang,Robert W. Siegel,Jinbiao Chen,Beverly A. Heinz,Richard E. Higgs,Nicole Kalleward,Kevin R. Jepson,Rodrigo Goya,Maia A. Smith,David Collins,Davide Pellacani,Ping Xiang,Valentine de Puyraimond,Marketa Ricicova,Lindsay Devorkin,Caitlin Pritchard,Kush Dalal,Pankaj Panwar,Harveer Dhupar,Fabian A. Garces,Courtney A. Cohen,John M. Dye,Kathleen E. Huie,Catherine V. Badger,Darwyn Kobasa,Darwyn Kobasa,Jonathan Audet,Jonathan Audet,Joshua J. Freitas,Saleema Hassanali,Ina Hughes,Luis Munoz,Holly C. Palma,Bharathi Ramamurthy,Robert W. Cross,Robert W. Cross,Thomas W. Geisbert,Thomas W. Geisbert,Vineet Menacherry,Kumari Lokugamage,Viktoriya Borisevich,Iliana Lanz,Lisa Anderson,Payal Sipahimalani,Kizzmekia S. Corbett,Lingshu Wang,Eun Sung Yang,Yi Zhang,Wei Shi,Barney S. Graham,John R. Mascola,Tara L. Fernandez,Carl L. Hansen,Ester Falconer,Bryan Edward Jones,Bryan C. Barnhart +66 more
TL;DR: The LY-CoV1404 as discussed by the authors antibody is a highly potent, neutralizing, SARS CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody identified from a convalescent COVID-19 patient approximately 60 days after symptom onset.
Journal ArticleDOI
Quantitative Proteomic Analyses of Influenza Virus-Infected Cultured Human Lung Cells
Kevin M. Coombs,Alicia R. Berard,Wanhong Xu,Oleg V. Krokhin,Xiaobo Meng,John P. Cortens,Darwyn Kobasa,Darwyn Kobasa,John A. Wilkins,Earl G. Brown +9 more
TL;DR: Gene ontology and pathway analyses indicated differentially regulated proteins and included those involved in host cell immunity and antigen presentation, cell adhesion, metabolism, protein function, signal transduction, and transcription pathways.